Research
You May Not Need the Full Dose Forever: Inside SURMOUNT-MAINTAIN
Medically reviewed by Dr. J. Adam, MD · Updated July 23, 2026 · Sources cited below
SURMOUNT-MAINTAIN randomised 378 adults who had reached a weight plateau after 60 weeks on tirzepatide at their maximum tolerated dose. Continuing at that dose maintained a 21.9% reduction, dropping to 5 mg maintained 16.6%, and switching to placebo fell back to 9.9%. It is the first dedicated randomised evidence that a reduced dose is a real alternative to stopping.
Key takeaways
- Published in The Lancet on 12 May 2026 (doi:10.1016/S0140-6736(26)00656-2).
- 441 enrolled, 378 randomised at week 60 after reaching a weight plateau.
- Continue maximum tolerated dose: −21.9%. Reduce to 5 mg: −16.6%. Placebo: −9.9%.
- Both active arms beat placebo decisively (p<0.0001).
- A reduced dose held most of the result but not all of it — the trade is real, not free.
| Publication | Lancet, published online 12 May 2026 |
|---|---|
| Identifiers | NCT06047548 · doi:10.1016/S0140-6736(26)00656-2 |
| Design | Phase 3b, 112-week, double-blind, placebo-controlled, 20 US sites |
| Randomised | 378 (441 enrolled) |
| Continue MTD | −21.9% bodyweight maintained |
| Reduce to 5 mg | −16.6% maintained |
| Placebo | −9.9% |
| Funding | Eli Lilly and Company |
What question did this finally answer?
SURMOUNT-4 had already established what happens when tirzepatide stops: substantial regain. But that trial compared continuing against stopping entirely. It said nothing about the option most patients and prescribers actually wanted to discuss — staying on treatment at a lower dose.
That gap mattered because the reasons people want to reduce are real. Cost scales with dose at many providers. Side effects can persist. And a maintenance phase can run for years, which makes the difference between a maximum dose and a lower one financially significant over time.
Until May 2026 the honest answer was that nobody knew. SURMOUNT-MAINTAIN is the first dedicated randomised trial to test it.
How was it designed?
Participants first completed a 60-week weight-loss period on tirzepatide at their maximum tolerated dose of 10 mg or 15 mg. Only those who reached a defined plateau — less than 5% bodyweight change between weeks 48 and 60 — were randomised, into three arms: continue at maximum tolerated dose, reduce to 5 mg, or switch to placebo. The randomised phase ran to week 112.
The plateau requirement is what makes the trial useful. It ensures the comparison starts from a stable point rather than mid-decline, so the question being answered is genuinely about maintenance rather than about continued loss.
How should the numbers be read?
The headline is that both active arms decisively beat placebo, so continuing treatment in some form is clearly better than stopping. That reinforces what the withdrawal evidence already showed.
The more interesting number is the gap between the two active arms. Reducing to 5 mg held 16.6% against 21.9% on the maximum tolerated dose — roughly three quarters of the result. That is a genuine trade rather than a free lunch, and it reframes the decision as a choice between two reasonable options rather than a search for the single correct one.
For someone whose main obstacle is cost or tolerability, giving up around five percentage points of bodyweight reduction to stay on treatment at a lower dose may be a clearly better outcome than stopping. For someone doing well at the higher dose with no barrier to continuing, the trial gives no reason to reduce.
What does it not settle?
Individual response varied, and the trial reports group means. Some participants on 5 mg held their result completely; others did not. The trial cannot predict which you would be.
It also studied one specific reduction — maximum tolerated dose down to 5 mg — rather than a range of intermediate doses, and it ran 112 weeks rather than years. Whether 5 mg holds at four or five years is not established. And none of this is a schedule you should apply yourself: dose changes belong with the prescriber who knows your response and history.
What does dose reduction do to the bill?
Dose and price are linked at most providers, either through explicit dose tiers or through the quantity of drug dispensed. A reduction from a maximum tolerated dose to 5 mg therefore usually produces a real monthly saving rather than a nominal one, and over a maintenance phase measured in years that compounds into a substantial figure.
That is what makes the trial commercially as well as clinically interesting. Before it, a patient asking to reduce dose for cost reasons was asking their prescriber to act without evidence. Now there is a randomised comparison to reason from, including an honest account of what the reduction costs in maintained weight.
The arithmetic is individual, and it should include any dose-related surcharge your provider applies above a threshold. Ask specifically what the monthly figure becomes at 5 mg versus at your current dose before assuming the saving is proportional — pricing tiers rarely move in straight lines.
View chart data as a table
| Continue maximum tolerated dose | 21.9% |
|---|---|
| Reduce to 5 mg | 16.6% |
| Switch to placebo | 9.9% |
View chart data as a table
| Series | Week 60 | Week 76 | Week 94 | Week 112 |
|---|---|---|---|---|
| Continue MTD | 21.9% | 22.1% | 22.0% | 21.9% |
| Reduce to 5 mg | 21.9% | 19.8% | 17.9% | 16.6% |
| Placebo | 21.9% | 17.2% | 13.0% | 9.9% |
| Factor | Continue MTD | Reduce to 5 mg |
|---|---|---|
| Weight reduction maintained | −21.9% | −16.6% |
| Versus placebo | −12.0 percentage points | −6.6 percentage points |
| Statistical significance | p<0.0001 | p<0.0001 |
| Typical monthly drug cost | Higher; dose surcharges common | Lower at most providers |
| Best suited to | Tolerating well, no cost barrier | Cost or tolerability is the obstacle |
| Evidence horizon | 112 weeks | 112 weeks |
Frequently asked questions
Can I lower my dose and keep the weight off?
SURMOUNT-MAINTAIN found 5 mg maintained 16.6% against 21.9% on the maximum tolerated dose and 9.9% on placebo. Most of the result held, but not all of it.
Is a lower dose as good as staying on the full dose?
No. It held roughly three quarters of the reduction. Whether that trade is worth it depends on your cost and tolerability situation.
Is this the same as microdosing?
No. This lowers an already-effective dose under supervision after a plateau. Microdosing starts below the studied range and has no randomised evidence.
Should I reduce my dose based on this?
That is a prescriber decision. This trial gives them evidence to work with; it is not a schedule to apply yourself.
How long did it run?
112 weeks total, with randomisation at week 60.
Sources
Every clinical claim above links to a primary source: an FDA record, a peer-reviewed publication with DOI or PMID, or a ClinicalTrials.gov registration. Where a figure could not be verified against a primary source, it is labelled rather than asserted.
rel="nofollow noopener". Rankings follow our
published methodology. See conflicts
of interest. This article is information, not medical advice.